Bio-Path Holdings (Nasdaq:BPTH) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BPTH 주식 개요

는 미국에서 임상 및 전임상 단계의 종양학에 중점을 둔 RNAi 나노입자 신약 개발 회사로 운영되고 있습니다.

BPTH 기본 분석
눈송이 점수
가치 평가	0/6
미래 성장	0/6
과거 실적	0/6
재무 상태	3/6
배당금	0/6

보상

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

마이너스 주주 지분

의미 있는 시가총액이 없습니다. ( $5M )

+ 2 더 많은 위험

Bio-Path Holdings, Inc. 경쟁사

Portage Biotech

NasdaqCM:PRTG

US$2.1m

Aravive

NasdaqGS:ARAV

US$2.9m

Genprex

NasdaqCM:GNPX

US$1.9m

Ensysce Biosciences

NasdaqCM:ENSC

US$3.0m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Bio-Path Holdings
과거 주가
현재 주가	US$1.49
52주 최고치	US$21.60
52주 최저치	US$1.31
베타	0.28
11개월 변경	-22.40%
3개월 변경 사항	-30.37%
1년 변경 사항	-81.14%
33년 변화	-98.60%
5년 변화	-99.39%
IPO 이후 변화	-99.95%

최근 뉴스 및 업데이트

Recent updates

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Nov 05

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Aug 16

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Jul 08

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Mar 24

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Aug 17

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully

Mar 26

주주 수익률

	BPTH	US Biotechs	US 마켓
7D	3.5%	2.7%	4.0%
1Y	-81.1%	15.4%	24.9%

수익률 대 산업: BPTH 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: BPTH 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is BPTH's price volatile compared to industry and market?
BPTH volatility
BPTH Average Weekly Movement	20.2%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.2%

안정적인 주가: BPTH 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: BPTH 의 주간 변동성( 24% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2007	10	Peter Nielsen	www.biopathholdings.com

는 미국에서 임상 및 전임상 단계의 종양학에 중점을 둔 RNAi 나노입자 약물 개발 회사로 운영되고 있습니다. 이 회사는 DNA를 파괴로부터 보호하기 위한 탈옥시리보핵산(DNA) 백본 변형인 P-에톡시를 사용하는 약물 전달 및 안티센스 기술 플랫폼인 DNAbilize를 기반으로 제품을 개발합니다. 주요 약물 후보로는 급성 골수성 백혈병(AML) 및 골수형성이상증후군 치료를 위한 임상 2상 시험 중인 프렉시게버센이 있습니다.

Bio-Path Holdings, Inc. 기본 사항 요약

Bio-Path Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BPTH 기본 통계
시가총액	US$3.14m
수익(TTM)	-US$13.96m
수익(TTM)	n/a

0.0x

P/S 비율

-0.2x

P/E 비율

BPTH 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BPTH 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$13.96m
수익	-US$13.96m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-6.71
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

BPTH 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BPTH 주식 개요

보상

위험 분석

Bio-Path Holdings, Inc. 경쟁사

NasdaqCM:PRTG

US$2.1m

NasdaqGS:ARAV

US$2.9m

NasdaqCM:GNPX

US$1.9m

NasdaqCM:ENSC

US$3.0m

가격 내역 및 성능

최근 뉴스 및 업데이트

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

Recent updates

Bio-Path Holdings, Inc. to Report Q2, 2024 Results on Aug 15, 2024

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress

Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding

New major risk - Negative shareholders equity

Bio-Path Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.209375 million.

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Bio-Path Holdings, Inc. Expands Global Patent Portfolio

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2 million.

New minor risk - Profitability

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $0.29925 million.

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(b)(1)

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $7.499995 million.

Bio-Path Holdings, Inc. to Report Q4, 2023 Results on Mar 08, 2024

Bio-Path Holdings, Inc. has withdrawn its Follow-on Equity Offering in the amount of $23.75 million.

New major risk - Share price stability

Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients

Bio-Path Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $19 million.

Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia

No longer forecast to breakeven

Bio-Path Holdings, Inc. to Report Q3, 2023 Results on Nov 15, 2023

Bio-Path Holdings, Inc., Annual General Meeting, Dec 14, 2023

Bio-Path Holdings, Inc. Receives Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Price target decreased by 7.7% to US$12.00

Bio-Path Holdings, Inc. to Report Q2, 2023 Results on Aug 15, 2023

New major risk - Shareholder dilution

New major risk - Share price stability

Bio-Path Holdings, Inc. Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

New major risk - Market cap size

New minor risk - Share price stability

Bio-Path Holdings, Inc. to Report Q1, 2023 Results on May 12, 2023

Forecast to breakeven in 2025

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q3, 2022 Results on Nov 15, 2022

We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate

Bio-Path Holdings, Inc., Annual General Meeting, Dec 15, 2022

Bio-Path Holdings, Inc. Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path GAAP EPS of -$0.42 beats by $0.07

Bio-Path Holdings, Inc. to Report Q2, 2022 Results on Aug 16, 2022

Is Bio-Path Holdings (NASDAQ:BPTH) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$11.00

Bio-Path Holdings, Inc. to Report Q1, 2022 Results on May 17, 2022

Price target increased to US$12.50

Less than half of directors are independent

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Bio-Path Holdings, Inc. Appoints Aline Sherwood to its Board of Directors

Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation

Bio-Path Holdings, Inc. to Report Fiscal Year 2021 Results on Mar 11, 2022

Insufficient new directors

Bio-Path Holdings, Inc. Announces Resignation of Martina Molsbergen as Member of the Board and All Committees of the Board

Bio-Path Holdings, Inc. Presents Data from Ongoing Phase 2 Study of Prexigebersen At 2021 American Society of Hematology Annual Meeting

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

Bio-Path Holdings (NASDAQ:BPTH) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$12.50

We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully